Rosiglitazone reduces plasma insulin & its precursors while decreasing glycaemia in type 2 diabetics.

被引：0
|
作者：
Jones, NP
Charbonnel, B
Lönnqvist, F
Owen, S
Patwardhan, R
机构：
来源：
DIABETOLOGIA | 1999年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
859
引用
下载
收藏
页码：A229 / A229
页数：1
相关论文
共 50 条
  • [11] Rosiglitazone improves insulin sensitivity by increasing plasma adiponectin and decreasing plasma resistin, and by reducing abdominal visceral adipose tissue in type 2 diabetic patients
    Nam, JY
    Kim, DM
    Park, JS
    Ahn, CW
    Kim, KR
    OBESITY RESEARCH, 2004, 12 : A42 - A42
  • [12] Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes
    Smith, SA
    Porter, LE
    Biswas, N
    Freed, MI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12): : 6048 - 6053
  • [13] Rosiglitazone reduces proinsulin/insulin ratio and improves β-cell function in type 2 diabetes
    Porter, LE
    Freed, MI
    Jones, NP
    Biswas, N
    DIABETOLOGIA, 2000, 43 : A192 - A192
  • [14] Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetics
    Yang, Jian
    Eliasson, Bjorn
    Smith, Ulf
    Cushman, Samuel W.
    Sherman, Arthur
    FASEB JOURNAL, 2012, 26
  • [15] Effects of Rosiglitazone on insulin resistance, CRP and adiponectin levels in Lebanese type 2 diabetics - A preliminary study
    Medlej, RC
    Gannage, MHE
    Halaby, GH
    DIABETES, 2005, 54 : A510 - A510
  • [16] Rosiglitazone (RSG) reduces insulin requirement and inflammatory marker in type 2 diabetic uremic patients.
    Li, PKT
    Szeto, CC
    Chow, KM
    Leung, CB
    Wong, TYH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 401A - 401A
  • [17] Insulin reduces plasma arginase activity in type 2 diabetic patients
    Kashyap, Sangeeta R.
    Lara, Abigail
    Zhang, Renliang
    Park, Young Mi
    DeFronzo, Ralph A.
    DIABETES CARE, 2008, 31 (01) : 134 - 139
  • [18] INSULIN PUMP TREATMENT REDUCES PLASMA APOPROTEIN (APO)-E AND TRIGLYCERIDE (TG) LEVELS IN TYPE-I DIABETICS
    GEORGOPOULOS, A
    APPLEBAUMBOWDEN, D
    MARGOLIS, S
    HAZZARD, W
    CIRCULATION, 1984, 70 (04) : 270 - 270
  • [19] INSULIN-PUMP TREATMENT REDUCES PLASMA APOPROTEIN-E AND TRIGLYCERIDE LEVELS IN TYPE-I DIABETICS
    GEORGOPOULOS, A
    APPLEBAUMBOWDEN, D
    MARGOLIS, S
    HAZZARD, W
    ARTERIOSCLEROSIS, 1984, 4 (05): : A557 - A557
  • [20] Insulin reduces plasma enzymatic arginase activity in patients with type 2 diabetes
    Kashyap, S. R.
    Lara, A.
    Zhang, R.
    Park, Y. M.
    Defronzo, R. A.
    DIABETOLOGIA, 2007, 50 : S298 - S298
12345